Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
Increased non high-density lipoprotein (HDL)/low-density lipoprotein (LDL) cholesterol levels are independent risk factors for cardiovascular (CV) mortality with no documented threshold. A new combination of nutraceuticals (berberine 200 mg, monacolin K 3 mg, chitosan 10 mg and coenzyme Q 10 mg) wit...
Main Authors: | Valentina Spigoni, Raffaella Aldigeri, Monica Antonini, Maria Maddalena Micheli, Federica Fantuzzi, Andrea Fratter, Marzia Pellizzato, Eleonora Derlindati, Ivana Zavaroni, Riccardo C. Bonadonna, Alessandra Dei Cas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/18/7/1498 |
Similar Items
-
Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
by: Adorni MP, et al.
Published: (2017-12-01) -
The role of nutraceuticals in the treatment of primary dyslipidemia
by: Elias Sanidas, et al.
Published: (2020-01-01) -
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
by: Dirk Müller-Wieland, et al.
Published: (2017-05-01) -
Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot
by: Longina Kłosiewicz-Latoszek, et al.
Published: (2021-03-01) -
HDL-C as a new therapeutic target in the treatment of dyslipidemia
by: Sahin I
Published: (2012-06-01)